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ABSTRACT
Objective To examine the overall treatment effect and
the proportion attributable to contextual effect (PCE) in
randomised controlled trials (RCTs) of diverse treatments
for osteoarthritis (OA).
Methods We searched Medline, Embase, Central,
Science Citation Index, AMED and CINAHL through
October 2014, supplemented with manual search of
reference lists, published meta-analyses and systematic
reviews. Included were RCTs in OA comparing placebo
with representative complementary, pharmacological,
non-pharmacological and surgical treatments. The
primary outcome was pain. Secondary outcomes were
function and stiffness. The effect size (ES) of overall
treatment effect and the PCE were pooled using
random-effects model. Subgroup analyses and meta-
regression were conducted to examine determinants of
the PCE.
Results In total, 215 trials (41 392 participants) were
included. The overall treatment effect for pain ranged
from the smallest with lavage (ES=0.46, 95% CI 0.24 to
0.68) to the largest with topical non-steroidal anti-
inﬂammatory drugs (ES=1.37, 95% CI 1.19 to 1.55).
On average, 75% (PCE=0.75, 95% CI 0.72 to 0.79) of
pain reduction was attributable to contextual effect. It
varied by treatment from 47% (PCE=0.47, 95% CI 0.32
to 0.70) for intra-articular corticosteroid to 91%
(PCE=0.91, 95% CI 0.60 to 1.37) for joint lavage.
Similar results were observed for function and stiffness.
Treatment delivered by needle/injection and other means
than oral medication, longer duration of treatment, large
sample size (≥100 per arm) and public funding source
were associated with increased PCE for pain reduction.
Conclusions The majority (75%) of the overall
treatment effect in OA RCTs is attributable to contextual
effects rather than the speciﬁc effect of treatments.
Reporting overall treatment effect and PCE, in addition
to traditional ES, permits a more balanced, clinically
meaningful interpretation of RCT results. This would help
dispel the frequent discordance between conclusions
from RCT evidence and clinical experience—the ‘efﬁcacy
paradox’.
INTRODUCTION
The beneﬁt of a treatment may result from the
speciﬁc effect of the treatment itself and the non-
speciﬁc effect from the context in which the treat-
ment is delivered.1 This non-speciﬁc effect is
commonly termed as placebo effect in clinical
trials,2 and placebo response or contextual effect in
clinical practice.3 However, the clinical impact of
the latter has largely been overlooked, especially
since the placebo effect in a randomised controlled
trial (RCT) is usually subtracted from the treatment
effect. In this situation, a treatment is only consid-
ered effective when it is clearly superior to placebo,
and it is this difference from placebo that is
reported in terms of the strength of the treatment.
However, in clinical practice, a treatment is
unavoidably delivered with contextual factors and
it is the overall effect of the treatment (speciﬁc plus
contextual effects) that is important to the patient.
A large number of studies have demonstrated that
contextual factors such as patient beliefs and
expectancy, the patient–practitioner interaction and
the environment have real therapeutic effects.3–5
These beneﬁts are often clinically signiﬁcant, espe-
cially in chronically painful or distressing
conditions.2 6
Osteoarthritis (OA) is the most common form of
arthritis. In the USA, it affects 27 million people or
12.1% of the adult population.7 8 Current treat-
ments mainly aim to relieve pain and stiffness and
to improve function and quality of life.9 However,
the beneﬁts from current available therapies are
relatively small and these may be outweighed by
side effects and other factors such as cost of deliv-
ery.10 Of 53 treatments, only two (opioid and
intra-articular corticosteroid injection) have been
reported to consistently reach the minimum clinic-
ally important difference (MCID) with an effect
size (ES) of 0.5 over placebo.9 10 This is equivalent
to 15% of pain reduction on a visual analogue
scale (VAS).11 Although the magnitude of an
acceptable MCID continues to be debated, it is
apparent that the additional beneﬁt of treatment
above placebo is not the only beneﬁt that a patient
receives from a treatment, both in RCTs and in
clinical practice. The sole focus on the separation
of treatment from placebo causes confusion to
practitioners when a treatment reported to have a
small ES in an RCT clearly produces clinically
important improvements in clinical practice. Such
common discordance between reported small treat-
ment effects in RCTs and guidelines and the
observed marked treatment effects in clinical prac-
tice presents an ‘efﬁcacy paradox’ to many patients
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and clinicians.12 This suggests the need for a change in emphasis
in the reporting and interpretation of results of placebo-
controlled RCTs. Based on this, this study examined the overall
treatment effect in RCTs and the proportion of that effect that
may be explained by placebo, rather than conventional separ-
ation of treatment from placebo, in an attempt to overcome this
‘efﬁcacy paradox’. For this ﬁrst exploration, we sampled speciﬁc
interventions aimed at managing OA, with different models of
action and delivery, including pharmaceutical, non-
pharmaceutical, surgical and complementary treatments, rather
than examine all treatments for OA.
METHODS
A systematic review (SR) and meta-analysis of randomised
placebo-controlled trials was performed.
Search strategy and selection criteria
A systematic search was undertaken using the Cochrane Library,
Medline (OVID), Embase (OVID), Web of Science, AMED and
CINAHL from inception to October 2014. Free texts and index
terms related to ‘osteoarthritis’, ‘randomised controlled trial’
and a speciﬁc treatment (eg, paracetamol or acetaminophen)
were used (see online supplementary search strategy). Reference
lists of included studies and published SRs and meta-analyses
were hand searched for additional eligible studies. No language
limitation was applied.
Studies meeting the following criteria were included: (1) ran-
domised placebo-controlled trial; (2) participants with OA of
any joint; (3) comparisons of placebo with active treatment
including chondroitin, glucosamine, paracetamol, oral non-
steroidal anti-inﬂammatory drugs (NSAIDs), topical NSAIDs,
pulsed electromagnetic ﬁeld therapy (PEMF), acupuncture,
intra-articular hyaluronic acid (IAHA), intra-articular corticoster-
oid (IACS) and joint lavage; (4) reporting at least one of the fol-
lowing outcomes: pain, function or stiffness; and (5) reporting
change from baseline and its SD or data that could derive them.
Data extraction and quality assessment
A standard data form was used to extract data of included
studies. Items recorded were study design and setting, character-
istics of participants (percentage of women, mean age), inter-
ventions (sessions, duration) and outcomes (at different time
points). Repeated measurements of change from baseline and its
SD were collected. If not presented, they were calculated from
outcomes at baseline and end points using a formula recom-
mend by the Cochrane Collaboration, that SD of the change
was adjusted for the correlation between baseline and endpoint
values.13 14 The correlation coefﬁcient was obtained from trials
that reported SD at both baseline, end point and of the change
from baseline. When more than one scale for the same outcome
was reported, for example, Western Ontario and McMaster
Universities Arthritis Index pain and VAS pain, only one scale
per outcome was selected using a published outcome measure
hierarchy.15
Study quality was assessed using the modiﬁed Jadad tool in
which allocation concealment was also assessed.13 16 Data were
fully extracted and assessed by a single investigator (KZ) and
validated by three other investigators (NA, XC and TS).
Discrepancies were discussed and ratiﬁed by a senior investigator
(WZ).
Statistical analysis
The overall treatment effect was deﬁned as the ES of active
treatment group, whereas the contextual effect was deﬁned as
the ES of the placebo group. The ES in terms of mean change
from baseline in the unit of its SD was calculated for each
group.14 The proportion attributable to contextual effect (PCE)
and its 95% CI were calculated using the ES ratio between the
contextual effect and the overall treatment effect.17
Theoretically, the PCE should range from 0 (which indicated no
contribution from contextual effects) to 1 (which indicated
100% contribution from contextual effects). When the ES of
contextual effects was greater than the ES of overall treatment
effects, the maximum of 1 (100%) was given. Trials in which
patients in either treatment or placebo group worsened from
baseline were excluded from the meta-analysis since (1) it may
be side/nocebo effect, which is not the focus of interest for the
PCE; and (2) the measure of PCE does not allow negative
values, especially when the ratio was log transformed.
The primary outcome measure was pain. Secondary outcome
measures were function and stiffness. The time point when the
ES of active treatment group reached its peak in each study was
chosen for meta-analyses. The heterogeneity of studies was
assessed using Q test and I2 index tests.13 18 Publication bias
was accessed using funnel plot and Egger’s test.19
Random-effects model was applied in all meta-analyses to
account for potential heterogeneity.
Subgroup analyses were performed to assess the effect of type
of treatment; sample size (≥100 per arm);20 duration of inter-
vention (at 4, 8, 13 and >13 weeks); route of treatment (oral,
PEMF, topical, needle/injection or surgery); chance of receiving
active treatment (number of active treatment arms/number of
treatment arms); allocation concealment (yes vs no); blinding of
participants (yes vs no) and setting of trials (primary care vs sec-
ondary care); funding source (public vs industry); and targeted
joint and country (developing vs developed). Random-effect
meta-regression was also conducted to assess the potential deter-
minants of the PCE for pain. All statistical tests were performed
using STATAV.11 (Stata Corp LP, Texas, USA).
RESULTS
Study selection
The literature search identiﬁed 17 165 citations. After initial
screening of titles and abstracts, 1039 potentially eligible cita-
tions were identiﬁed. Of those, 824 citations were excluded
after reading full papers. Finally, 215 studies were included in
the meta-analysis (ﬁgure 1).
Characteristics of included studies
From the 215 studies, 41 392 participants were included in the
analysis. The median age of patients was 62.2 (IQR 60.0 to
64.2) years; median percentage of women was 65.8% (IQR
60.0% to 72.8%); pooled baseline pain was 54.8 (95% CI 50.8
to 58.9) on the 0–100 scale; median duration of symptoms was
6.8 (IQR 5.0 to 8.7) years; and the median duration of study
was 12 (IQR 4 to 13) weeks. The main methodological limita-
tion was lack of allocation concealment, which was the case in
about 50% (109/215) of trials. Details of summarised study
characteristics by treatment are shown in table 1. Publication
bias was apparent (Egger test p<0.001), that is, trials with
smaller PCE (larger difference between treatment and placebo
groups) were more likely to be published, which generally had a
smaller sample size (ﬁgure 2). This was coherent with the
funnel plot of standardised mean difference (SMD) of treatment
over placebo, which showed that trials with larger SMD
between the two groups were more likely to be published (see
online supplementary ﬁgure S1).
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Overall treatment effect and the PCE
Of the 11 selected treatments, the overall treatment effect for
pain was smallest with lavage (ES=0.46, 95% CI 0.24 to 0.68)
and largest with topical NSAIDs (ES=1.37, 95% CI 1.19 to
1.55) (table 2), the PCE in these two treatments being 91% and
85%, respectively. On average, 75% of the overall treatment
effects for pain in OA were explained by contextual effects
(PCE=0.75, 95% CI 0.72 to 0.79) (table 2). The PCE, from the
highest to the lowest, was 0.91 (95% CI 0.60 to 0.137) for
lavage, 0.87(95% CI 0.73 to 1.03) for paracetamol, 0.85 (95%
CI 0.77 to 0.93) for topical NSAIDs, 0.85 (95% CI 0.74 to
0.97) for acupuncture, 0.82 (95% CI 0.75 to 0.90) for IAHA,
0.80 (95% CI 0.64 to 0.99) for PEMF, 0.76 (95% CI 0.62 to
0.93) for glucosamine plus chondroitin, 0.70 (95% CI 0.65 to
0.75) for NSAIDs, 0.68 (95% CI 0.55 to 0.84) for chondroitin,
0.67 (95% CI 0.53 to 0.84) for glucosamine, and 0.47 (95% CI
0.32 to 0.70) for IACS. Figure 2 presents the hierarchy of the
overall treatment effect for each active treatment and their PCE.
Similar results were observed for function and stiffness (table 2).
Four studies of pain and one study of stiffness in which placebo
group worsened were excluded from meta-analyses (ﬁgure 3).
Determinants of PCE
Subgroup analysis
Sample size
Comparing the results from all trials, the PCE was higher in
larger trials. In trials with >100 participants per arm, the PCE
for pain reduction was 0.85 (95% CI 0.68 to 1.05) with chon-
droitin, 0.79 (95% CI 0.61 to 1.03) with glucosamine, 0.79
(95% CI 0.64 to 0.98) with glucosamine plus chondroitin, 0.85
(95% CI 0.70 to 1.03) with paracetamol, 0.72 (95% CI 0.66 to
0.78) with NSAIDs, 0.92 (95% CI 0.85 to 0.99) with topical
NSAIDs, 0.91 (95% CI 0.82 to 1.01) with IAHA, and 0.98
(95% CI 0.86 to 1.12) with acupuncture (see online supplemen-
tary table S1).
Route of delivery
The PCE was lowest when the treatment was delivered by oral
medication (PCE=0.70, 95% CI 0.66 to 0.75), higher when
delivered via physical means, for example, PEMF (PCE=0.80,
95% CI 0.64 to 0.99) or by use of needles/injection
(PCE=0.81, 95% CI 0.75 to 0.88), and highest with more inva-
sive or surgical interventions, for example, joint lavage
(PCE=0.91, 95% CI 0.60 to 1.37). In addition, the PCE with
topical NSAIDs (PCE=0.85, 95% CI 0.77 to 0.93) was higher
than its counterpart oral NSAIDs (PCE=0.70, 95% CI 0.70 to
0.65) (see online supplementary table S2).
Other determinants
The PCE was signiﬁcantly higher in trials that applied allocation
concealment (PCE=0.81, 95% CI 0.76 to 0.85) than in trials
that did not (PCE=0.70, 95% CI 0.66 to 0.75), were conducted
in developed countries and publicly funded, and with longer
duration of treatment. However, the PCE was not signiﬁcantly
affected by the targeted joint, the chance of receiving the active
treatment or the setting (primary care vs secondary care) in
which the treatment was received (see online supplementary
table S2).
Meta-regression
In meta-regression of PCE for pain, 467 observations were
included. The PCE signiﬁcantly increased in treatments involv-
ing needles or injection (β=0.119, 95% CI 0.056 to 0.182,
p=0.000), physical therapy, for example, PEMF (β=0.208, 95%
CI 0.029 to 0.387, p=0.023), and topical cream (β=0.174,
95% CI 0.104 to 0.244, p=0.000). It also signiﬁcantly
increased with longer duration of treatment (β=0.002, 95% CI
0.001 to 2.310, p=0.021), when sample size was larger than
100 per arm (β=0.177, 95% CI 0.121 to 0.232, p=0.000) and
when trials were public funded (β=0.086, 95% CI 0.018 to
0.155, p=0.014). Other contextual factors such as baseline
pain, mean age, percentage of women, chance of receiving
active treatment and methodological aspects were not found to
be signiﬁcant determinants after adjustment for other factors
(see online supplementary table S3).
DISCUSSION
This study focused on the overall treatment effect and the per-
centage of that effect that is attributable to contextual (placebo)
effects (PCE). Using placebo-controlled RCT data in OA, we
examined a sample of contrasting treatments including comple-
mentary medicines, nutraceuticals, oral drugs, topical NSAIDs,
compounds administered through intra-articular injection and
joint lavage. We found that the overall treatment effect of these
11 diverse treatments in reducing OA pain ranged from 0.46 SD
( joint lavage) to 1.37 SD (topical NSAIDs), of which 91% of
the improvement with lavage and 85% of the improvement
with topical NSAIDs is explained by contextual effects. On
average, the contextual effect contributed 75% to the overall
treatment effect for the included treatments for pain in OA. We
also found that PCE varied across treatments, ranging from the
lowest with IACS (0.47, 95% CI 0.32 to 0.70) to the highest
with joint lavage (0.91, 95% CI 0.60 to 1.37). Two factors
known to inﬂuence the magnitude of placebo effect in OA
RCTs, the mode of delivery and sample size of the study,2 also
affected the magnitude of the PCE. The ﬁnding on sample size
reafﬁrmed the ‘small study effect’ where smaller trials often
report larger beneﬁt of treatment over placebo, in which, as a
ratio between ES of placebo and treatment, PCE would be
smaller. This ﬁnding corresponds with the ﬁndings of our
funnel plot. PCE also increased with longer duration of treat-
ment and in trials with public funding source. Other factors
Figure 1 Flow chart of study selection.
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such as percentage of women and methodological aspects did
not affect the size of the PCE.
Although this is the ﬁrst study in OA for PCE, the ﬁndings
accord with those of SRs examining treatment of other chronic
conditions. Kirsch and colleagues have reported that 75% of the
overall drug effect of antidepressants can be explained by
placebo effect.21 A more recent study using RCT data in all dis-
eases found that the non-speciﬁc effects (contextual effects)
account for roughly 60% of all treatment effects with variation
between conditions.22
In the ﬁrst RCTundertaken in 1945 examining the efﬁcacy of
streptomycin in tuberculosis, the treatment effect was deﬁned as
the difference between outcomes in the treatment and placebo
groups.23 Since then, the separation of the treatment from the
placebo group in terms of improved outcomes has been the
main focus of interest in all RCTs. No published RCTs exam-
ined in this review have presented results as overall treatment
effect and PCE, and even when the overall treatment effect was
very large, all conclusions concerning efﬁcacy were based solely
on the difference between treatment and placebo groups. As far
as we are aware, no other placebo-controlled RCTs in OA or
other musculoskeletal conditions have used this method of
expressing the results and we believe that this is also true in
other disease areas.
There are several clinical implications for these ﬁndings. First,
the overall treatment effects of the OA therapies examined are
moderate to large with the majority being well above the clinic-
ally signiﬁcant level of the current MCID (0.5 SD) suggested by
the National Institute for Health and Care Excellence.9 This
important observation is contrary to the general opinion that
most treatments for OA are relatively weak, which encourages
pessimism concerning treatment of people with OA.
Second, ordering these treatments according to strength of
overall treatment ES gives a very different hierarchy to that
obtained when ordered according to traditional standardised ES
derived from the separation of treatment from placebo. This
change in focus from speciﬁc to overall treatment ES more
accurately reﬂects the real beneﬁt that patients might expect
from these treatments in clinical practice and better informs
clinicians and patients about expected treatment outcomes.
Third, the majority of beneﬁt obtained from treatments in
OA derives from contextual rather than speciﬁc treatment
effects, emphasising the potential importance and magnitude of
contextual response in patient care. For example, while the
overall effect of paracetamol is 0.65 (95% CI 0.46 to 0.83),
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Figure 2 Funnel plot of LnPCE for pain in osteoarthritis. PCE,
proportion attributable to contextual effect, Egger test p<0.001.
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87% of this is attributable to contextual effects (PCE=0.87,
95% CI 0.73 to 1.03). This provides some explanation as to
why paracetamol may have little beneﬁt on its own—an
‘impure’ placebo.
Furthermore, presentation of overall treatment effect and
PCE provides a solution for the ‘efﬁcacy paradox’.12 Taking
IAHA and IACS as examples, although the overall treatment
effect of IAHA (1.16) was slightly higher than IACS (0.97),
Table 2 Overall treatment effect size (ES) and proportion attributable to contextual effects (PCEs)
Outcome Treatment No. of trials No. of patients
Overall treatment
ES (95% CI)
I2% of overall
treatment ES PCE (95% CI) I2% of PCE
Pain Oral
Glucosamine 19 2512 1.06 (0.85 to 1.28) 88 0.67 (0.53 to 0.84) 63
Chondroitin 13 2562 1.29 (1.09 to 1.50) 85 0.68 (0.55 to 0.84) 67
Glucosamine + chondroitin 4 778 0.89 (0.27 to 1.51) 92 0.76 (0.62 to 0.93) 0
Paracetamol 7 2377 0.65 (0.46 to 0.83) 87 0.87 (0.73 to 1.03) 12
NSAID 62 18 145 1.11 (1.02 to 1.20) 92 0.70 (0.65 to 0.75) 51
Physical/topical
PEMF 18 1005 0.98 (0.75 to 1.20) 78 0.80 (0.64 to 0.99) 0
Topical NSAIDs 20 4399 1.37 (1.19 to 1.55) 90 0.85 (0.77 to 0.93) 35
Needle/injection
Acupuncture 17 2747 0.99 (0.81 to 1.18) 85 0.85 (0.74 to 0.97) 20
IACS 9 502 0.97 (0.67 to 1.28) 75 0.47 (0.32 to 0.70) 0
IAHA 35 4782 1.16 (1.01 to 1.31) 87 0.82 (0.75 to 0.90) 23
Surgical
Lavage 4 434 0.46 (0.24 to 0.68) 54 0.91 (0.60 to 1.37) 0
Overall 208 40 243 1.09 (1.03 to 1.14) 90 0.75 (0.72 to 0.79) 42
Function Oral
Glucosamine 20 2849 1.10 (0.88 to 1.31) 90 0.64 (0.49 to 0.82) 69
Chondroitin 12 1924 0.98 (0.80 to 1.17) 81 0.63 (0.47 to 0.85) 61
Glucosamine+chondroitin 5 1058 0.71 (0.32 to 1.10) 90 0.85 (0.71 to 1.02) 0
Paracetamol 4 1373 0.73 (0.49 to 0.97) 83 0.92 (0.78 to 1.09) 0
NSAIDs 44 14 613 1.02 (0.94 to 1.10) 88 0.64 (0.59 to 0.70) 50
Physical/topical
PEMF 17 914 0.66 (0.47 to 0.84) 69 0.63 (0.47 to 0.84) 0
Topical NSAIDs 17 3717 1.34 (1.10 to 1.58) 93 0.71 (0.58 to 0.87) 81
Needle/injection
Acupuncture 12 2453 1.01 (0.78 to 1.23) 89 0.85 (0.72 to 1.00) 38
IACS 6 421 0.62 (0.29 to 0.95) 80 0.68 (0.40 to 1.18) 0
IAHA 25 3315 1.02 (0.87 to 1.18) 84 0.84 (0.74 to 0.96) 23
Surgical
Lavage 4 425 0.47 (0.15 to 0.78) 77 0.93 (0.62 to 1.40) 0
Overall 166 33 062 0.98 (0.93 to 1.04) 89 0.71 (0.67 to 0.75) 56
Stiffness Oral
Glucosamine 9 1568 1.20 (0.77 to 1.63) 95 0.82 (0.63 to 1.05) 39
Chondroitin 2 793 0.48 (0.12 to 0.83) 88 1.00 (0.77 to 1.30) 0
Glucosamine+chondroitin 2 707 0.57 (−0.05 to 1.18) 92 0.91 (0.72 to 1.15) 0
Paracetamol 3 644 0.63 (0.31 to 0.95) 83 0.95 (0.72 to 1.24) 0
NSAIDs 29 8750 0.91 (0.84 to 0.99) 78 0.73 (0.67 to 0.80) 20
Physical/topical
PEMF 6 378 0.49 (0.22 to 0.76) 66 0.71 (0.43 to 1.17) 0
Topical NSAIDs 10 2578 1.01 (0.80 to 1.23) 90 0.93 (0.84 to 1.03) 0
Needle/injection
Acupuncture 7 1181 0.93 (0.67 to 1.20) 80 0.79 (0.66 to 0.94) 0
IACS 3 168 0.65 (0.22 to 1.08) 72 0.83 (0.34 to 2.04) 0
IAHA 3 2462 0.83 (0.67 to 1.00) 82 0.88 (0.77 to 1.00) 0
Surgical
Lavage 2 267 0.28 (0.04 to 0.53) 44 1.00 (0.46 to 2.16) 0
Overall 91 19 490 0.83 (0.79 to 0.87) 87 0.83 (0.79 to 0.87) 1
IACS, intra-articular corticosteroid; IAHA, intra-articular hyaluronic acid; NSAIDs, non-steroidal anti-inflammatory drugs; PEMF, pulsed-electromagnetic field therapy.
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contextual effects explain much more of the effect of IAHA
than they do for IACS (IAHA 82% vs IACS 47%) and this helps
to explain why IAHA may be effective in the clinical setting but
not in RCTs. Patient expectancy from IAHA may be enhanced
by being told that hyaluronic acid is a relatively new treatment,
that it is a natural product, that it has beneﬁcial effects on the
cartilage and joint tissues, and is very effective for OA pain, and
this may result in a good postinjection outcome. In contrast,
IACS is an old treatment and steroid is a considered a potent
drug with recognised potential side effects, so proportionally
more of its beneﬁts in many clinical contexts may need to reside
on its speciﬁc treatment effects.24
Therefore, when reporting RCTs, focusing on the overall treat-
ment ES of a particular treatment is likely to provide a better idea
of what to expect in routine care than emphasising the ES based
solely on the difference between treatment and placebo.
Furthermore, explaining to practitioners the proportion of a
treatment effect that is explained by contextual effects empha-
sises the importance of context in daily clinical practice. Even the
initial relief of severe pain from parenteral opioids, when the
patient knows they are receiving it, predominantly results from
contextual effects and expectancy.25 Practitioners may, therefore,
be encouraged to optimise their patient–practitioner interaction
and other contextual factors that are within their control.24
There are several limitations to this study. First, we did not
examine all treatments for OA but selected a sample of treat-
ments that varies in terms of mechanism of action and mode of
delivery. Although we investigated a range of representatives OA
treatments including non-pharmacological, pharmacological,
surgical and complementary treatments, it is possible that our
ﬁndings of a generally good high overall treatment ES and a
high PCE will not be conﬁrmed in other treatments for OA in
placebo-controlled clinical trials. Furthermore, some important
treatments for OA such as exercise, education, weight loss and
arthroplasty are not readily amenable to a placebo or sham
intervention, and in the absence of placebo-controlled rando-
mised trials, it is very difﬁcult to estimate the contribution of
contextual effect to such interventions, just as it is difﬁcult to
estimate their traditional ES over placebo.
Second, the new hierarchy based on overall treatment effect
shows topical NSAIDs, with its large PCE (85%) to be the best
treatment for OA pain. However, it is hard to believe that
topical NSAIDs are better than IACS in terms of overall treat-
ment ES. It is possible that differences in patient selection may
help to explain this apparent discrepancy. For example, patients
selected for trials of IACS or surgical treatments may be more
likely to be those experiencing unrelieved pain and may be more
difﬁcult to treat than patients with less resilient symptoms who
more commonly may be selected for trials of topical NSAIDs and
oral medications. This could have explained why participants in
trials of topical NSAIDs show larger improvement from baseline
than those in trials of IACS. However, we examined baseline
pain and duration of disease/pain of patients in trials of different
treatments and no apparent differences were found. This suggests
that differences in other contextual factors, such as participant
expectancy (largely inﬂuenced by the trial information received),
treatment experience and participant–practitioner interaction,
may be responsible for this result. However, we were unable to
examine these patient-level contextual factors as they were rarely
measured and reported in clinical trials, which is also the case for
the PCE. Though proxy indicators such as chance of receiving
active treatment and percentage of women in each trial were
examined in meta-regression of PCE, they may be less sensitive
to change. Thus, further study using individual patient data is
warranted.
Since this is the ﬁrst time that the overall treatment effect and
PCE have been examined in OA, much of the interpretation of
the hierarchy and proportions of speciﬁc and contextual effects
has yet to be discovered. Further study is, therefore, warranted
to better understand this. As the large overall treatment ES esti-
mated in this study contains contextual effect, which include the
regression to the mean or the Hawthorn effect, care must be
taken when applying this measure. It should never be used
alone but with the PCE.
Figure 3 The overall treatment effect and the proportion attributable to contextual effect (PCE) for pain in osteoarthritis. The overall length of the
bar represents the effect size (ES) of overall treatment effect; the blue component of the bar and the label represents the PCE of each treatment
(measured by ratio of the ESs between contextual effect and overall treatment effect, ranging from no contribution from contextual effect (=0) to
100% contribution from contextual effect (=1); the red component represent the proportion attributable to speciﬁc effect of each treatment). CS,
chondroitin sulfate; GS, glucosamine sulfate; IACS, intra-articular corticosteroid; IAHA, intra-articular hyaluronic acid; NSAID, non-steroidal
anti-inﬂammatory drug; PEMF, pulsed-electromagnetic ﬁeld therapy.
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Third, the contextual effect investigated in this study is a
combination of placebo effect and other spontaneous effects,
such as the Hawthorne effect, natural ﬂuctuation in disease and
regression to the mean. However, the PCE is not a measure that
only counts the placebo group effect, but a measure that counts
both the placebo and treatment group effects. In such a situ-
ation, other spontaneous effects such as regression to the mean
and the Hawthorn effect (being observed) are subtracted in the
log transform calculation. Such a simple estimate provides a
clinically useful tool to estimate the PCE without further exam-
ination for other spontaneous effects, which are often not meas-
urable from the trial data. Nevertheless, more research is
warranted to investigate these components of the contextual
effect and their roles in overall treatment effect.
Finally, we made no attempt to identify unpublished trials as
do many other SRs. However, unpublished trials are more likely
to have insigniﬁcant ﬁndings and a smaller separation between
treatment and placebo, a higher PCE would be expected.
Therefore, by not including unpublished studies the PCE found
in our study is more likely to be a conservative estimate of the
true PCE.
In conclusion, this study suggests that the overall treatment
beneﬁts from diverse treatments of OA are more than those
reported in RCTs and predominantly result from the contextual
effects rather than the speciﬁc effects of treatments. Reporting
the overall treatment effect and the PCE together, in addition to
traditional difference between treatment and placebo, helps to
better translate RCT evidence into clinical practice, reduces the
‘efﬁcacy paradox’ and emphasises to practitioners the import-
ance of contextual factors in clinical care. More research is
needed to identify key contextual factors that may work on
their own in a generic fashion or which may show interactions
with speciﬁc treatment effects.
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